The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Vecuronium     [ (2S,3S,5S,8R,9S,10S,13S,14S,16 S,17S)-17...

Synonyms: CHEBI:9939, CHEMBL1201219, SureCN13575838, HMS2090D22, DB01339, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Vecuronium

  • Prolonged neuromuscular blockade after the termination of long-term treatment with vecuronium is associated with metabolic acidosis, elevated plasma magnesium concentrations, female sex, and probably more important, the presence of renal failure and high plasma concentrations of 3-desacetylvecuronium [1].
  • Neuromuscular paralysis lasting up to seven days may occur after the termination of long-term administration (i.e., more than two days) of vecuronium in critically ill patients [1].
  • In the patients without prolonged neuromuscular blockade, the mean (+/- SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5 +/- 1.0 ml per kilogram of body weight per minute, 299 +/- 154 minutes, and 1.1 +/- 0.6 liters per kilogram, respectively [1].
  • Pharmacokinetic studies in obesity show that the behaviour of molecules with weak or moderate lipophilicity (e.g. lithium and vecuronium) is generally rather predictable, as these drugs are distributed mainly in lean tissues [2].
  • The mechanism of the bradycardia produced by vecuronium is unclear [3].

High impact information on Vecuronium


Chemical compound and disease context of Vecuronium


Biological context of Vecuronium


Anatomical context of Vecuronium


Associations of Vecuronium with other chemical compounds


Gene context of Vecuronium

  • The interaction of three new non-depolarizing neuromuscular blocking agents--atracurium, vecuronium and Duador--on human red cell acetylcholinesterase (AChE; EC and human plasma butyrylcholinesterase (BuChE; EC was investigated [25].
  • T1/control twitch height and TOF ratio (T4/T1) in the N-TOF group were higher than those in the C-TOF group 80-120 min and 100-120 min after administration of vecuronium, respectively [26].
  • In the vecuronium and succinylcholine groups, CD4/CD8 fractions decreased in the postoperative period [27].
  • It was determined that vecuronium is a strong inhibitor of HNMT; apparent Ki = 1 microM [28].
  • Therefore, transepithelial transport of the P-gp substrate vinblastine, the steroidal (type 2) cation vecuronium, the relatively small (type 1) cationic compound azidoprocainamide methoiodide and the aliphatic cation tri-n-butylmethylammonium were measured [29].

Analytical, diagnostic and therapeutic context of Vecuronium


  1. Persistent paralysis in critically ill patients after long-term administration of vecuronium. Segredo, V., Caldwell, J.E., Matthay, M.A., Sharma, M.L., Gruenke, L.D., Miller, R.D. N. Engl. J. Med. (1992) [Pubmed]
  2. Effects of obesity on pharmacokinetics implications for drug therapy. Cheymol, G. Clinical pharmacokinetics. (2000) [Pubmed]
  3. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Cembala, T.M., Sherwin, J.D., Tidmarsh, M.D., Appadu, B.L., Lambert, D.G. Br. J. Pharmacol. (1998) [Pubmed]
  4. Intraoperative monitoring of motor evoked potentials: a review of 116 cases. Nagle, K.J., Emerson, R.G., Adams, D.C., Heyer, E.J., Roye, D.P., Schwab, F.J., Weidenbaum, M., McCormick, P., Pile-Spellman, J., Stein, B.M., Farcy, J.P., Gallo, E.J., Dowling, K.C., Turner, C.A. Neurology (1996) [Pubmed]
  5. Vesicular uptake system for the cation lucigenin in the rat hepatocyte. Braakman, I., Pijning, T., Verest, O., Weert, B., Meijer, D.K., Groothuis, G.M. Mol. Pharmacol. (1989) [Pubmed]
  6. Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. Shanks, C.A., Avram, M.J., Fragen, R.J., O'Hara, D.A. Clin. Pharmacol. Ther. (1987) [Pubmed]
  7. Vecuronium kinetics and dynamics in anesthetized infants and children. Fisher, D.M., Castagnoli, K., Miller, R.D. Clin. Pharmacol. Ther. (1985) [Pubmed]
  8. Neuromuscular block. Bowman, W.C. Br. J. Pharmacol. (2006) [Pubmed]
  9. A comparison of systemic and regional hemodynamic effects of d-tubocurarine, pancuronium, and vecuronium. Saxena, P.R., Dhasmana, K.M., Prakash, O. Anesthesiology (1983) [Pubmed]
  10. Drug actions at mammalian motor nerve endings: the suppression of neostigmine-induced fasciculations by vecuronium and isoflurane. Baker, T., Stanec, A. Anesthesiology (1987) [Pubmed]
  11. The effects of isoflurane and desflurane on intracranial pressure, cerebral perfusion pressure, and cerebral arteriovenous oxygen content difference in normocapnic patients with supratentorial brain tumors. Fraga, M., Rama-Maceiras, P., Rodiño, S., Aymerich, H., Pose, P., Belda, J. Anesthesiology (2003) [Pubmed]
  12. The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. Heier, T., Clough, D., Wright, P.M., Sharma, M.L., Sessler, D.I., Caldwell, J.E. Anesthesiology (2002) [Pubmed]
  13. Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. Guay, J., Grenier, Y., Varin, F. Clinical pharmacokinetics. (1998) [Pubmed]
  14. Vecuronium for muscle relaxation in patients with myasthenia gravis. Buzello, W., Noeldge, G., Krieg, N., Brobmann, G.F. Anesthesiology (1986) [Pubmed]
  15. The cardiovascular effects of vecuronium (ORG NC45) and pancuronium in patients undergoing coronary artery bypass grafting. Morris, R.B., Cahalan, M.K., Miller, R.D., Wilkinson, P.L., Quasha, A.L., Robinson, S.L. Anesthesiology (1983) [Pubmed]
  16. Insights into the increased oxygen demand during chest physiotherapy. Horiuchi, K., Jordan, D., Cohen, D., Kemper, M.C., Weissman, C. Crit. Care Med. (1997) [Pubmed]
  17. Carotid body chemoreceptor function is impaired by vecuronium during hypoxia. Wyon, N., Joensen, H., Yamamoto, Y., Lindahl, S.G., Eriksson, L.I. Anesthesiology (1998) [Pubmed]
  18. Prejunctional effects of vecuronium in the cat. Baker, T., Aguero, A., Stanec, A., Lowndes, H.E. Anesthesiology (1986) [Pubmed]
  19. Improving the design of muscle relaxant studies. Stabilization period and tetanic recruitment. Lee, G.C., Iyengar, S., Szenohradszky, J., Caldwell, J.E., Wright, P.M., Brown, R., Lau, M., Luks, A., Fisher, D.M. Anesthesiology (1997) [Pubmed]
  20. Neuromuscular blocking drugs do not alter the pupillary light reflex of anesthetized humans. Gray, A.T., Krejci, S.T., Larson, M.D. Arch. Neurol. (1997) [Pubmed]
  21. Quantification of the aminosteroidal non-depolarizing neuromuscular blocking agents rocuronium and vecuronium in plasma with liquid chromatography-tandem mass spectroscopy. Gutteck-Amsler, U., Rentsch, K.M. Clin. Chem. (2000) [Pubmed]
  22. Priming doses of atracurium and vecuronium depress swallowing in humans. D'Honneur, G., Gall, O., Gerard, A., Rimaniol, J.M., Lambert, Y., Duvaldestin, P. Anesthesiology (1992) [Pubmed]
  23. Onset of maximum neuromuscular block following succinylcholine or vecuronium in four age groups. Koscielniak-Nielsen, Z.J., Bevan, J.C., Popovic, V., Baxter, M.R., Donati, F., Bevan, D.R. Anesthesiology (1993) [Pubmed]
  24. Physostigmine prevents postanesthetic shivering as does meperidine or clonidine. Horn, E.P., Standl, T., Sessler, D.I., von Knobelsdorff, G., Büchs, C., Schulte am Esch, J. Anesthesiology (1998) [Pubmed]
  25. Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases. Foldes, F.F., Deery, A. British journal of anaesthesia. (1983) [Pubmed]
  26. Nicorandil accelerates recovery of neuromuscular block caused by vecuronium. Saitoh, Y., Kaneda, K., Fujii, Y., Oshima, T. Canadian journal of anaesthesia = Journal canadien d'anesthésie. (2001) [Pubmed]
  27. Modification of mediators of immune reaction after general anaesthesia. Sánchez Palacios, A., Ortiz Ponce, M., Rodríguez Pérez, A., Schamann Medina, F., García Marrero, J.A. Allergologia et immunopathologia. (2004) [Pubmed]
  28. Vecuronium inhibits histamine N-methyltransferase. Futo, J., Kupferberg, J.P., Moss, J., Fahey, M.R., Cannon, J.E., Miller, R.D. Anesthesiology (1988) [Pubmed]
  29. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. Smit, J.W., Weert, B., Schinkel, A.H., Meijer, D.K. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  30. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Bryson, H.M., Faulds, D. Drugs (1997) [Pubmed]
  31. Atracurium or vecuronium for rapid sequence endotracheal intubation. Lennon, R.L., Olson, R.A., Gronert, G.A. Anesthesiology (1986) [Pubmed]
WikiGenes - Universities